Microbot Medical
Braintree, United States · Biotechnology, Healthcare, Health Care · 37 employees
Microbot Medical’s vision is to improve the quality of life of millions of patients globally by advancing robotic technologies to perform surgical procedures within the human body, and offer physicians and their patients less invasive and more precise solutions. The company’s innovations tap into one of the fastest-growing spaces in the medical field, the minimal invasive space. Microbot Medical d
Funding history
- Funding Round — $25.2M — Sep 2025
- Funding Round — $13.0M — Feb 2025
- Funding Round — $7.0M — Jan 2025
- Funding Round — $8.6M — Jan 2025
- Funding Round — $1.8M — Jun 2024
Recent signals
- Jan 12, 2026: SEC 8-K (8.01): On January 12, 2026, Microbot Medical Inc. issued a press release that reaffirms its achievements for 2025 and outlines key milestones expected for 2026. The announcement highlights the company's strategic focus on growth and innovation, although specific financial figures or detailed timelines are not mentioned. This press release serves to inform investors and the market of the company's outlook and goals, inviting stakeholder engagement based on anticipated future developments. The press release is provided as Exhibit 99.1 to the filing.
- Nov 26, 2025: SEC 8-K (1.01): On November 26, 2025, Microbot Medical Inc. announced a key agreement with Emory University Hospital, marking it as the first hospital globally to adopt the Company’s LIBERTY® Endovascular Robotic System for patient care. This collaboration also involves establishing an Endovascular Robotics Program in interventional radiology at Emory. This partnership signifies a strategic move into robotic surgical technologies and reflects a commitment to advancing medical practices through innovation. The financial terms of the collaboration were not disclosed, but this development is anticipated to enhance the Company’s market positioning in the healthcare sector.
- Oct 16, 2025: Launched Microbot Medical Inc. launches the LIBERTY® System for interventional oncology.
- Oct 14, 2025: Microbot Medical Partners with U.S. Logistics Company to Support LIBERTY® System Commercialization.
- Sep 30, 2025: Raised $25.2M
- Mar 04, 2025: Microbot Medical Appoints Paul Mullen as Vice President of Sales for LIBERTY® Endovascular Robotic System
- Feb 18, 2025: Raised $13.0M
- Jan 22, 2025: Raised $7.0M
See plans & pricing → Track Microbot Medical’s funding, hiring, and signals — with verified contacts — on Fundz.